June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Topical steroids vs anti-Vegf in experimental corneal neovascularization: differential efficacy, microscopic features and genomic response
Author Affiliations & Notes
  • Pierfrancesco Mirabelli
    Department of Ophthalmology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Anthony Mukwaya
    Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Anton Lennikov
    Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Maria Xeroudaki
    Department of Ophthalmology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Beatrice Peebo
    Department of Ophthalmology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Neil S Lagali
    Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
  • Footnotes
    Commercial Relationships   Pierfrancesco Mirabelli, None; Anthony Mukwaya, None; Anton Lennikov, None; Maria Xeroudaki, None; Beatrice Peebo, None; Neil Lagali, None
  • Footnotes
    Support  County council of Östegötland, Sweden. Cronqvist stiftelse, Sweden.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1011. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Pierfrancesco Mirabelli, Anthony Mukwaya, Anton Lennikov, Maria Xeroudaki, Beatrice Peebo, Neil S Lagali; Topical steroids vs anti-Vegf in experimental corneal neovascularization: differential efficacy, microscopic features and genomic response. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1011.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pathologic angiogenesis is involved in cancer and several blinding conditions, like wet AMD, proliferative retinopathies and corneal neovascularization. Among available treatments, anti-VEGF often shows limited efficacy, while steroids are potentially responsible for many side-effects. We performed a series of linked studies to assess the efficacy of topical dexamethasone relative to anti-VEGF in a corneal model of experimental neovascularization, and the effect on microscopic features in vivo and on gene expression.

Methods : Male Wistar rats were sutured intrastromally in right corneas 1.5 mm from the temporal limbus. Thereafter, treatment was given with dexamethasone, rat specific anti-Vegf, or goat IgG (control), topically QID for 2-7 days. Slit lamp photography to assess and quantify macroscopic vessel growth, and in vivo confocal microscopy to study cell infiltration and limbal vessel dilation, and detect microscopic vessel sprouts, were performed longitudinally. Genomic analysis with RNA Microarray, selected gene expression with q-RTPCR, and selected protein expression in tissue (immunohistochemistry, immunofluorescence, western blot) were performed at 48 hours, during the early pre-sprouting phase.

Results : At day 7, dexamethasone suppressed corneal neovascularization more than anti-Vegf (90% vs. 14%). No difference was detectable concerning cell infiltration on IVCM at 48 hours, but only dexamethasone inhibited limbal vessel dilation (p < 0,01). Microarray at 48 hours showed that in dexamethasone treated cornea 511 fewer genes were differentially expressed relative to naïve corneas, compared to anti-Vegf and IgG. Among the differentially expressed genes, several major and novel angiogenic and pro-inflammatory factors and chemokines were suppressed only by dexamethasone.

Conclusions : More effective treatments of corneal inflammation and neovascularization with less side-effects are needed. In this study several potential novel factors and mechanisms are identified that are not addressed by anti-VEGF therapy, and therefore represent interesting targets for further study.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×